Study of inflammatory markers (C-reactive protein & tumor necrosis factor-α) in moderate to severe obstructive sleep apnea hypopnea syndrome (OSAHS) and their response to treatment with nasal continuous positive airway pressure (nCPAP)

G. D‘Souza, H. Parikh, T. Vinod George (Bangalore, India)

Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing

Session: Systemic consequences of sleep-disordered breathing
Session type: E-Communication Session
Number: 2845

Disease area: Sleep and breathing disorders

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. D‘Souza, H. Parikh, T. Vinod George (Bangalore, India). Study of inflammatory markers (C-reactive protein & tumor necrosis factor-α) in moderate to severe obstructive sleep apnea hypopnea syndrome (OSAHS) and their response to treatment with nasal continuous positive airway pressure (nCPAP). Eur Respir J 2009; 34: Suppl. 53, 2845

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Effect of continuous positive airway pressure treatment (CPAP) in angiogenic growth factors‘ expression in patients with COPD and obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases Year: 2010
Catecholamines and obstructive sleep apnea (OSA) severity: response to positive airway pressure (PAP) therapy Source: Annual Congress 2009 - Continuous positive airway pressure therapy in obstructive sleep apnoea Year: 2009
Evaluation of long-term effect of continuous positive airway pressure (CPAP) therapy on reduction of high sensitivity C-reactive protein (HSCRP) for patients with obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 357s Year: 2005
Angiogenic factors in obstructive sleep apnea syndrome (OSA). Effects of nasal continuous positive airway pressure treatment (CPAP) Source: Annual Congress 2010 - Biomarkers for oxidative stress, inflammation and cardiovascular function in sleep apnoea Year: 2010
Prediction of effective continuous positive airway pressure (CPAP) in obstructive sleep apnea syndrome (OSA) Source: Eur Respir J 2005; 26: Suppl. 49, 111s Year: 2005
Prevalence and causes of residual sleepiness (RS) 12 months after continuous positive airway pressure (CPAP) treatment for obstructive sleep apnea syndome (OSAS) Source: Annual Congress 2010 - Sleep disorders: neurology, smoking and daytime sleepiness Year: 2010
CPAP decreases plasma levels of soluble tumour necrosis factor-α receptor 1 in obstructive sleep apnoea Source: Eur Respir J 2008; 32: 1009-1015 Year: 2008
Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA). Source: Virtual Congress 2020 – Pathophysiology and treatment of obstructive sleep apnoea Year: 2020
Influence of nasal obstruction (NO) on obstructive sleep apnea (OSA) severity and continuous positive airway pressure (CPAP) adaptation problems Source: Annual Congress 2010 - The upper airway and oral appliances Year: 2010
Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA) Source: Sleep and Breathing Conference 2021 Year: 2021
Positional obstructive sleep apnea (OSA) and automatic positive airway pressure (APAP) therapy Source: Annual Congress 2012 - Technology, screening and questionnaires in OSA Year: 2012
Association between obstructive sleep apnea (OSA) and depression and the effect of continuous positive airway pressure (CPAP) treatment Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology Year: 2012
Effect of continuous positive airway pressure (CPAP) treatment on proangiogenic factors of angiogenesis in obstructive sleep apnea (OSA) patients Source: Eur Respir J 2005; 26: Suppl. 49, 39s Year: 2005
Comparison of auto-adjusting and fixed positive airway pressure therapy in patients with mild to moderate obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2003; 22: Suppl. 45, 95s Year: 2003
The influence of 3-weeks‘ therapy of continous positive airway pressure (CPAP) on serum leptin and homocysteine concentration in patients with obstructive sleep apnea (OSA) Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005
Effects of continuous positive airway pressure (CPAP) on quality of life in patients with obstructive sleep apnea syndromes (OSAS) Source: Annual Congress 2010 - Clinical aspects of sleep apnoea Year: 2010
Prevalence and determinants of residual excessive daytime sleepiness (RES) in patients treated with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA). Source: Virtual Congress 2020 – Advance in treatments for sleep and breathing disorders and long-term adherence Year: 2020
Outcomes in patients with REM-related obstructive sleep apnoea (REM-OSA) treated with continuous positive airway pressure (CPAP) Source: International Congress 2019 – Treatment of continuous positive airway pressure and monitoring of its effects Year: 2019
Effect of continuous positive airway pressure treatment on hypoadiponectinemia in male patients with obstructive sleep apnea syndrome Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005
Effects of continuous positive airways pressure (CPAP) on portal flow in patients with obstructive apnoea syndrome (OSAS) Source: Eur Respir J 2007; 30: Suppl. 51, 321s Year: 2007